Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $5.90 USD
Change Today +0.32 / 5.73%
Volume 1.5M
SGMO On Other Exchanges
SGMO is not on other exchanges.
As of 8:10 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

sangamo biosciences inc (SGMO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $19.25
52 Week Low
09/30/15 - $5.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

sangamo biosciences inc (SGMO) Related Businessweek News

No Related Businessweek News Found

sangamo biosciences inc (SGMO) Details

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. Its proprietary zinc finger DNA-binding protein (ZFP) technology enables precise and highly specific genome modification and gene regulation. The company’s ZFPs can be linked to functional domains that regulate gene expression to create ZFP transcription factors (ZFP TFs) capable of activating or repressing a targeted gene. The ZFPs can also be linked to endonuclease domains to create zinc finger nucleases (ZFNs), which enable precise genome editing to facilitate the disruption of a specific gene or the targeted addition of a new gene or DNA sequence into the genome cells, without the detrimental consequences of off-target DNA binding activity. The Company’s lead ZFP Therapeutic candidate is SB-728-T, a ZFN-mediated autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS). Sangamo BioSciences also has proprietary preclinical stage ZFP Therapeutic programs for lysosomal storage disorders such as Hunter and Hurler syndromes. In addition, the company has preclinical programs in hemophilia A and B, and Huntington’s disease in collaboration with Shire International GmbH; and hemoglobinopathies, such as beta-thalassemia and sickle cell disease in collaboration with Biogen Inc. Sangamo also has strategic partnerships with Sigma-Aldrich Corporation; Dow AgroSciences, LLC; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd; and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.

102 Employees
Last Reported Date: 02/25/15
Founded in 1995

sangamo biosciences inc (SGMO) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $650.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $405.0K
Chief Medical Officer and Vice President of T...
Total Annual Compensation: $440.0K
Executive Vice President of Research and Deve...
Total Annual Compensation: $460.0K
Compensation as of Fiscal Year 2014.

sangamo biosciences inc (SGMO) Key Developments

Sangamo BioSciences, Inc. Announces Approval by Recombinant DNA Advisory Committee Of ZFP Therapeutic Phase 1 Study Protocol For First In Vivo Genome Editing Application

Sangamo BioSciences Inc. announced unanimous approval by the National Institutes of Health'sRecombinant DNA Advisory Committee (RAC) of a Phase 1 study protocol for a ZFP Therapeutic as a potential curative therapy for hemophilia B. The Factor IX program will be the first clinical study of in vivo genome editing and therapeutic application of Sangamo's In Vivo Protein Replacement Platform (IVPRP). Sangamo expects to file an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) by the end of 2015 and, pending FDA clearance, plans to initiate a Phase 1 clinical trial in 2016.

Sangamo Biosciences Inc. - Special Call

To revise their January 2012 collaboration and license agreement to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease with Shire plc

Sangamo BioSciences, Inc. and Shire plc Restructures Collaboration to Accelerate Development of ZFP Therapeutics for the Treatment of Hemophilia and Huntington's Disease

Sangamo BioSciences Inc. announced that the company and its collaborator, Shire plc have agreed to revise their January 2012 collaboration and license agreement to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease. The decision to restructure reflects a strategic decision by both Shire and Sangamo to focus efforts in areas of current interest and expertise for each company. Under the revised terms of the agreement, Shire will return to Sangamo the exclusive world-wide rights to gene targets for the development, clinical testing and commercialization of ZFP Therapeutics for hemophilia A and B. Shire will retain rights and will continue to develop ZFP Therapeutic clinical leads for Huntington's disease and a ZFP Therapeutic for one additional gene target yet to be named. Shire's rights with respect to other targets contemplated in the original agreement revert to Sangamo. Under the revised agreement, each company is responsible for expenses associated with its own programs and will reimburse the other for any ongoing services provided. Sangamo has granted Shire a right of first negotiation to license the hemophilia A and B programs. No milestone payments will be made on any program and each company will pay certain royalties to the other on commercial sales up to a specified maximum cap. Additional financial details of the agreement will not be disclosed.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGMO:US $5.90 USD +0.32

SGMO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cellectis SA €24.07 EUR +0.23
Fibrocell Science Inc $3.78 USD +0.06
REGENXBIO Inc $22.19 USD +3.18
Spark Therapeutics Inc $43.93 USD +1.57
uniQure NV $20.90 USD -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation SGMO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.4x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANGAMO BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at